Prime Medicine
- Chun Lin Chou
Chun Lin Chou has a diverse work experience spanning various scientific roles in the biotechnology and pharmaceutical industries. Currently, Chou works as a Senior Associate Scientist at Prime Medicine, Inc. since April 2023. Prior to that, Chou held a position as a Senior Research Associate at Moderna from October 2020 to April 2023. In March 2020, Chou worked as an Associate Scientist at Sanofi.
Chou also has experience as a Process Development Scientist at Eurofins from June 2019 to February 2020, where they focused on automation and troubleshooting in high-throughput instrumentation and executed purification studies for mAbs and Proteins. Before that, Chou worked as a Purification Chemist at AmbioPharm from January 2019 to May 2019, performing peptide purification processes in a cGMP environment.
Chou's earlier experience includes working as an Independent Researcher at the University of South Carolina in 2018 and as an Undergraduate Researcher at the Medical University of South Carolina from August 2017 to December 2017. Chou also served as an Assistant Researcher at Taipei Medical University for a brief period from May 2016 to July 2016.
Chun Lin Chou obtained an Associate of Arts and Sciences - AAS degree in Science from Midlands Technical College. Following this, Chun Lin Chou pursued further education and earned a Bachelor's degree in Biochemistry and Molecular Biology from the University of South Carolina.
Location
Cambridge, United States
Links
Previous companies
Org chart
This person is not in the org chart
Offices
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
Ad